A Study of Medical Records From Children With Central Precocious Puberty (CPP) in China
PACTURE
Patient Characteristics, Treatment Patterns, and Resource Usage in Children Diagnosed With Central Precocious Puberty (CPP) in China
1 other identifier
observational
1,477
1 country
5
Brief Summary
The main purpose is to describe how many children were treated during 24 months or less because of CPP and how treatment worked for them. There are no participants in this trial, the study only involves reviewing participants medical past and current records and collecting information.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Dec 2023
5 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 18, 2022
CompletedFirst Posted
Study publicly available on registry
April 22, 2022
CompletedStudy Start
First participant enrolled
December 13, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 27, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
August 27, 2025
CompletedJanuary 21, 2026
January 1, 2026
1.7 years
April 18, 2022
January 16, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Percentage of Participants With CPP Treatment
Up to approximately 10 years
Secondary Outcomes (3)
Percentage of Participants With CPP Treatment at Baseline
At Baseline
Percentage of Participants With Luteinizing hormone (LH) Suppression
Baseline up to approximately 10 years
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)
Up to approximately 10 years
Study Arms (1)
All Participants With CPP
Pediatric participants who have been diagnosed with CPP, who are currently or previously undergoing with gonadotropin-releasing hormone agonist (GnRHa) treatment between 2015, and 31 December 2024 will be assessed retrospectively using the Chinese CPP Big Data Platform database.
Eligibility Criteria
Pediatric participants with a diagnosis of CPP who are currently or previously undergoing GnRHa treatment between 2015 and 31 December 2024 will be enrolled in this study.
You may qualify if:
- Participants diagnosed with CPP and treated with GnRHa from the centers participating in this study within the Chinese CPP Big Data Platform database since 2015 to 2024.
- CPP diagnosis is based on the clinical assessment and description by CPP specialized doctors.
You may not qualify if:
- Not received GnRHa as the treatment for CPP.
- No available data for analysis.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Takedalead
Study Sites (5)
The Second Affiliated Hospital of Guangxi Medical University
Nanning, Guangxi, 530007, China
Hainan Women and Children's Medical Center
Haikou, Hainan, 570206, China
Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology
Wuhan, Hubei, 430030, China
Shandong Provincial Hospital Affiliated to Shandong First Medical University
Jinan, Shandong, 250021, China
Tianjin Medical University General Hospital
Tianjin, Tianjin Municipality, 300052, China
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Study Director
Takeda
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 18, 2022
First Posted
April 22, 2022
Study Start
December 13, 2023
Primary Completion
August 27, 2025
Study Completion
August 27, 2025
Last Updated
January 21, 2026
Record last verified: 2026-01
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, CSR
- Access Criteria
- IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/ For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.